H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc.






